Quantum Genomics Société Anonyme

BST:2QG Stock Report

Market Cap: €3.6m

Quantum Genomics Société Anonyme Past Earnings Performance

Past criteria checks 0/6

Quantum Genomics Société Anonyme's earnings have been declining at an average annual rate of -17.2%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 33.8% per year.

Key information

-17.2%

Earnings growth rate

4.0%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate33.8%
Return on equity-1,113.5%
Net Margin-90,752.2%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Quantum Genomics Société Anonyme makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BST:2QG Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 230-1830
31 Mar 231-2230
31 Dec 223-2530
30 Sep 223-2120
30 Jun 225-2030
31 Mar 225-1940
31 Dec 216-1740
30 Sep 217-1850
30 Jun 218-1850
31 Mar 216-1750
31 Dec 204-1640
30 Sep 204-1440
30 Jun 200-1020
31 Mar 200-1030
31 Dec 192-1040
30 Sep 190-930
30 Jun 190-1030
31 Mar 190-1130
31 Dec 180-1220
30 Sep 180-1220
30 Jun 180-1220
31 Mar 180-1020
31 Dec 170-920
30 Sep 170-820
30 Jun 170-720
31 Mar 170-620
31 Dec 160-520
30 Sep 160-520
30 Jun 160-520
31 Mar 160-420
31 Dec 150-420
30 Sep 150-310
30 Jun 150-310
31 Mar 150-210
31 Dec 140-210
30 Sep 140-210
30 Jun 140-210
31 Mar 140-210
31 Dec 130-210

Quality Earnings: 2QG is currently unprofitable.

Growing Profit Margin: 2QG is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2QG is unprofitable, and losses have increased over the past 5 years at a rate of 17.2% per year.

Accelerating Growth: Unable to compare 2QG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2QG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).


Return on Equity

High ROE: 2QG has a negative Return on Equity (-1113.46%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.